Qlt Inc (QLTI) 3.99 $QLTI
Global Glaucoma Treatment Market: Trends and Opportunities 2014-2019
M2 - Wed Oct 15, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h5f725/global_glaucoma) has announced the addition of the "Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)" report to their offering. This report includes detailed information on market size and share by type of drugs in glaucoma treatment sector. It also discusses key growth drivers, challenges and trends of the market. The market for glaucoma treatment has grown rapidly in the last decade, based on both increasing number of people with glaucoma and the introduction of new treatments. However, the worldwide glaucoma treatment market is expected to decline that can be attributable to price reduction of drugs due to generic availability of many brands in coming years. The glaucoma pharmaceuticals are segmented into two classes namely prostaglandins analogues (PGAs) and Non PGAs that include beta blockers, carbonic anhydrase inhibitors and alpha agonists. PGAS are the most widely prescribed drug class for glaucoma with latanoprost (brand name Xalatan) the most commonly prescribed drug. Key growth drivers of the market include rising ageing population, healthcare expenditures, medical coverage and new innovative combination drugs. The market players in medication as well as devices segments are totally different and somewhat very fragmented. Leaders in glaucoma medication space include Pfizer Inc, Alcon Inc. (Novartis), Allergan Inc and Merck and Co, Inc. Companies developing glaucoma drug-delivery devices include Ocular Therapeutix Inc, QLT Inc, pSivida Corp, Icon Bioscience Inc, Amorphex Therapeutics LLC, Euclid Systems Corp and Replenish Inc. In glaucoma laser market, top market leaders include Ellex, Lumenis, Quantel and Lightmed. Key Topics Covered: 1. Executive Summary 2. Glaucoma: A Major Cause of Vision Loss 3. Global Eye Care Market: An Analysis 4. Global Glaucoma Treatment Market: An Analysis 5. Regional Analysis: Glaucoma Treatment Market 6. Market Dynamics: Global Glaucoma Treatment Market 7. Competitive Landscape: Glaucoma Treatment Market 8. Company Profiles: Glaucoma Treatment Market For more information visit http://www.researchandmarkets.com/research/h5...l_glaucoma
AGN: 186.16 (+6.91), QLTI: 3.99 (unch), NVS: 88.61 (+0.71)
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene
PR Newswire - Tue Oct 14, 7:30AM CDT
Today, Analysts Review released its research reports regarding Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Lakeland Industries Inc. (NASDAQ: LAKE), Endo International plc (NASDAQ: ENDP), Actavis plc (NYSE: ACT) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7148-100free.
ENDP: 63.73 (+2.29), ACT: 232.13 (+5.46), QLTI: 3.99 (unch), AUXL: 31.12 (+0.53), LAKE: 14.94 (+0.01), CELG: 94.97 (+2.97), CELGZ: 3.57 (-0.14)
Endo to Buy Auxilium for $2.6B, Diversify Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 4:45PM CDT
Endo (ENDP) is set to acquire Auxilium Pharmaceuticals (AUXL) for $2.6 billion in cash as well as stock.
ENDP: 63.73 (+2.29), ACT: 232.13 (+5.46), QLTI: 3.99 (unch), AUXL: 31.12 (+0.53)
Market Maker Surveillance Report. FE, PBR, QLTI, CTSO, AGNC, BABA, Highest Net Buy Volume With Lowest Price Friction For Thursday, October 9th 2014
M2 - Fri Oct 10, 4:35AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4573 companies with "abnormal" market making, 961 companies with positive Friction Factors and 4314 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Thursday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Firstenergy Corp (NYSE:FE), Petroleo Brasileiro SA Petrobras (NYSE
BR), QLT INC (NASDAQ:QLTI), CytoSorbents Corp (OTC:CTSO), American Capital Agency Corp (NASDAQ:AGNC), (NYSE:BABA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
PBR: 13.20 (-0.80), QLTI: 3.99 (unch), FE: 35.21 (+0.27), AGNC: 22.84 (+0.18), BABA: 90.90 (+2.64)
Endo Buyout Of Auxilium Joins Two Changing Firms
at Investor's Business Daily - Thu Oct 09, 6:00PM CDT
Endo International inked a deal to buy fellow specialty drugmaker Auxilium Pharmaceuticals Thursday after raising its initial bid by nearly 20% to $2.6 billion in cash and stock, or $33.25 a share. Auxilium's shares rose 9% to 32.44, while Endo's...
ENDP: 63.73 (+2.29), VRX: 130.38 (+5.60), QLTI: 3.99 (unch), AUXL: 31.12 (+0.53), VVUS: 3.47 (+0.02)
Nasdaq stocks posting largest volume increases
AP - Thu Oct 09, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
OFED: 18.50 (unch), QLTI: 3.99 (unch), QLT.TO: 4.49 (+0.01), TILE: 15.51 (+0.09), UNIS: 3.77 (+0.02), ARWR: 6.80 (+0.23), FSBW: 16.80 (+0.03), GTWN: 16.14 (-0.11), DYNT: 3.76 (-0.06), JAXB: 11.54 (+0.49), KFX: 6.04 (-0.01), OBCI: 4.41 (+0.21), ISSC: 2.72 (+0.17), AUXL: 31.12 (+0.53), ORBT: 2.42 (-0.08), LAKE: 14.94 (+0.01), GTIV: 19.39 (unch)
How Endo International's $2.6B Deal for Auxilium Benefits Shareholders
at The Street - Thu Oct 09, 12:53PM CDT
With this deal for Auxilium, Endo has just turned itself into a top-tier global specialty health care leader.
ENDP: 63.73 (+2.29), ABT: 42.39 (+0.93), QLTI: 3.99 (unch), ACT: 232.13 (+5.46), AUXL: 31.12 (+0.53)
Why Auxilium Pharmaceuticals Inc. Stock Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Thu Oct 09, 10:07AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Auxilium Pharmaceuticals soared over 10%...
QLTI: 3.99 (unch), AUXL: 31.12 (+0.53)
Stock Futures Down, Off Lows; Alcoa, United, Auxilium Rise
at Investor's Business Daily - Thu Oct 09, 8:10AM CDT
Stock futures trimmed losses agressively ahead of Thursday's open, after positive weekly unemployment numbers. Dow futures were down 54.2 points, but well above early lows. Nasdaq 100 futures traded 5.8 points below fair market value, halving their...
BLDP: 2.87 (unch), ENDP: 63.73 (+2.29), QLTI: 3.99 (unch), AA: 16.35 (+0.66), PLUG: 4.41 (-0.04), AUXL: 31.12 (+0.53), UAL: 49.51 (+2.22)
Endo Intl to buy Auxilium in deal worth $2.6B
By TOM MURPHY - AP - Thu Oct 09, 7:37AM CDT
Ireland's Endo International is planning to buy Auxilium Pharmaceuticals in a sweetened cash-and-stock deal valued at $2.6 billion a few weeks after Auxilium rejected a lower bid. The Auxilium board embraced the latest offer but its shareholders get to vote on it.
ENDP: 63.73 (+2.29), QLTI: 3.99 (unch), QLT.TO: 4.49 (+0.01), AUXL: 31.12 (+0.53)
QLT Announces Merger With Auxilium Pharmaceuticals, Inc. Terminates for Superior Proposal
GlobeNewswire - Thu Oct 09, 5:47AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
announces that it has been advised by Auxilium Pharmaceuticals, Inc. ("Auxilium" that Auxilium's board of directors has reviewed an offer from Endo International plc ("Endo" to acquire all of the issued and outstanding shares of Auxilium (the "Endo Proposal" and, after consulting with its financial advisors and outside legal counsel, has determined that the Endo Proposal is a superior proposal under the terms of the Agreement and Plan of Merger (the "Merger Agreement" among QLT, Auxilium, QLT Holding Corp., and QLT Acquisition Corp., dated June 25, 2014. Accordingly, Auxilium has delivered a notice of termination of the Merger Agreement and has, in accordance with the Merger Agreement, agreed to concurrently pay to QLT a termination fee in the amount of US$28.4 million.
QLTI: 3.99 (unch), QLT.TO: 4.49 (+0.01), AUXL: 31.12 (+0.53)
QLT Enters Oversold Territory
MarketNewsVideo.com - Thu Sep 25, 12:39PM CDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
QLTI: 3.99 (unch)
The Zacks Analyst Blog Highlights: Auxilium Pharmaceuticals, QLT, Endo International, Gilead and Regeneron
PR Newswire - Thu Sep 25, 9:04AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Auxilium Pharmaceuticals (Nasdaq:AUXL-Free Report), QLT Inc. (Nasdaq:QLTI-Free Report), Endo International plc (Nasdaq:ENDP-Free Report), Gilead (Nasdaq:GILD-Free Report) and Regeneron (Nasdaq:REGN-Free Report).
QLTI: 3.99 (unch), AUXL: 31.12 (+0.53)
Biotech Stock Roundup: Auxilium an Acquisition Target, Amgen Submits another BLA - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 24, 10:05AM CDT
Auxilium Pharmaceuticals' (AUXL) shares soared almost 45% on a $2.2 billion acquisition proposal from Endo.
ENDP: 63.73 (+2.29), QLTI: 3.99 (unch), VRTX: 108.16 (+3.39), SHPG: 185.80 (+1.21), AUXL: 31.12 (+0.53), ALXN: 174.48 (+6.28), AMGN: 144.09 (+6.58), ABBV: 56.29 (+1.88), REGN: 381.01 (+14.88)
Auxilium Pharmaceuticals Favors QLT Deal Over Endo Bid - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 1:54PM CDT
Auxilium Pharmaceuticals (AUXL) has rejected Endo's (ENDP) offer.
ENDP: 63.73 (+2.29), QLTI: 3.99 (unch), AUXL: 31.12 (+0.53), AMGN: 144.09 (+6.58)
Auxilium Says Endo Takeover Offer Undervalues Company
at Investor's Business Daily - Mon Sep 22, 3:38PM CDT
Auxilium Pharmaceuticals' (AUXL) board said Monday that a $2.2 billion takeover offer from Endo International "significantly undervalues" the company. But the specialty-drug maker stopped short of an outright rejection of the unsolicited takeover bid...
ENDP: 63.73 (+2.29), QLTI: 3.99 (unch), AUXL: 31.12 (+0.53)
QLT Provides Further Update on Merger With Auxilium Pharmaceuticals, Inc.
GlobeNewswire - Mon Sep 22, 7:07AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" announces that it has been advised by Auxilium Pharmaceuticals, Inc. ("Auxilium" that Auxilium's board of directors (the "Auxilium Board" has reviewed the unsolicited offer from Endo International plc ("Endo" to acquire all of the issued and outstanding shares of Auxilium (the "Endo Proposal" and, after consulting with its independent financial and legal advisors, has unanimously determined that the Endo Proposal is not a superior proposal under the terms of the Agreement and Plan of Merger (the "Merger Agreement" among QLT, Auxilium, QLT Holding Corp., and QLT Acquisition Corp., dated June 25, 2014. Auxilium has further advised that the Auxilium Board has unanimously reaffirmed its recommendation that Auxilium's stockholders vote in favor of the adoption of the Merger Agreement, and has not withdrawn, modified, withheld, changed or qualified its recommendation with respect to the proposed merger with QLT pursuant to the Merger Agreement.
QLTI: 3.99 (unch), QLT.TO: 4.49 (+0.01), AUXL: 31.12 (+0.53)
Auxilium Pharma rejects Endo's takeover offer
AP - Mon Sep 22, 6:45AM CDT
CHESTERBROOK, Pa. (AP) — Auxilium Pharmaceuticals Inc.'s board has rejected an approximately $1.4 billion unsolicited takeover offer from Ireland's Endo International PLC.
ENDP: 63.73 (+2.29), QLTI: 3.99 (unch), QLT.TO: 4.49 (+0.01), AUXL: 31.12 (+0.53)
Auxilium Provides Transaction Update
PR Newswire - Mon Sep 22, 6:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that its Board of Directors (the "Board" has reviewed the unsolicited, non-binding and conditional proposal from Endo International plc ("Endo" and, after consulting with its independent financial and legal advisors, has unanimously determined it is not a superior proposal under the terms of its existing merger agreement with QLT Inc. ("QLT" and has unanimously reaffirmed its recommendation that Auxilium's stockholders vote in favor of the adoption of such merger agreement. In addition, the Board has determined that Endo's proposal significantly undervalues Auxilium. However, under the terms of the merger agreement with QLT, Auxilium maintains the right to engage in discussions with Endo and other third parties, subject to certain conditions in the merger agreement.
QLTI: 3.99 (unch), AUXL: 31.12 (+0.53)
Nasdaq stocks posting largest percentage decreases
AP - Thu Sep 18, 12:18PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ALCS: 0.30 (+0.01), QLTI: 3.99 (unch), QLT.TO: 4.49 (+0.01), RTRX: 9.49 (-0.11), BRID: 8.50 (+0.01), LPCN: 4.88 (+0.08), RPRX: 6.02 (-0.21), NYNY: 6.64 (-0.01), NVC.TO: 6.14 (+0.19), PEIX: 11.55 (unch), DGLY: 12.99 (-0.15), NVCN: 5.26 (+0.04)
Global Glaucoma Treatment Market: Trends and Opportunities 2014-2019
M2 - Wed Oct 15, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h5f725/global_glaucoma) has announced the addition of the "Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)" report to their offering. This report includes detailed information on market size and share by type of drugs in glaucoma treatment sector. It also discusses key growth drivers, challenges and trends of the market. The market for glaucoma treatment has grown rapidly in the last decade, based on both increasing number of people with glaucoma and the introduction of new treatments. However, the worldwide glaucoma treatment market is expected to decline that can be attributable to price reduction of drugs due to generic availability of many brands in coming years. The glaucoma pharmaceuticals are segmented into two classes namely prostaglandins analogues (PGAs) and Non PGAs that include beta blockers, carbonic anhydrase inhibitors and alpha agonists. PGAS are the most widely prescribed drug class for glaucoma with latanoprost (brand name Xalatan) the most commonly prescribed drug. Key growth drivers of the market include rising ageing population, healthcare expenditures, medical coverage and new innovative combination drugs. The market players in medication as well as devices segments are totally different and somewhat very fragmented. Leaders in glaucoma medication space include Pfizer Inc, Alcon Inc. (Novartis), Allergan Inc and Merck and Co, Inc. Companies developing glaucoma drug-delivery devices include Ocular Therapeutix Inc, QLT Inc, pSivida Corp, Icon Bioscience Inc, Amorphex Therapeutics LLC, Euclid Systems Corp and Replenish Inc. In glaucoma laser market, top market leaders include Ellex, Lumenis, Quantel and Lightmed. Key Topics Covered: 1. Executive Summary 2. Glaucoma: A Major Cause of Vision Loss 3. Global Eye Care Market: An Analysis 4. Global Glaucoma Treatment Market: An Analysis 5. Regional Analysis: Glaucoma Treatment Market 6. Market Dynamics: Global Glaucoma Treatment Market 7. Competitive Landscape: Glaucoma Treatment Market 8. Company Profiles: Glaucoma Treatment Market For more information visit http://www.researchandmarkets.com/research/h5...l_glaucoma
AGN: 186.16 (+6.91), QLTI: 3.99 (unch), NVS: 88.61 (+0.71)
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene
PR Newswire - Tue Oct 14, 7:30AM CDT
Today, Analysts Review released its research reports regarding Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Lakeland Industries Inc. (NASDAQ: LAKE), Endo International plc (NASDAQ: ENDP), Actavis plc (NYSE: ACT) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7148-100free.
ENDP: 63.73 (+2.29), ACT: 232.13 (+5.46), QLTI: 3.99 (unch), AUXL: 31.12 (+0.53), LAKE: 14.94 (+0.01), CELG: 94.97 (+2.97), CELGZ: 3.57 (-0.14)
Endo to Buy Auxilium for $2.6B, Diversify Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 4:45PM CDT
Endo (ENDP) is set to acquire Auxilium Pharmaceuticals (AUXL) for $2.6 billion in cash as well as stock.
ENDP: 63.73 (+2.29), ACT: 232.13 (+5.46), QLTI: 3.99 (unch), AUXL: 31.12 (+0.53)
Market Maker Surveillance Report. FE, PBR, QLTI, CTSO, AGNC, BABA, Highest Net Buy Volume With Lowest Price Friction For Thursday, October 9th 2014
M2 - Fri Oct 10, 4:35AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4573 companies with "abnormal" market making, 961 companies with positive Friction Factors and 4314 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Thursday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Firstenergy Corp (NYSE:FE), Petroleo Brasileiro SA Petrobras (NYSE
BR), QLT INC (NASDAQ:QLTI), CytoSorbents Corp (OTC:CTSO), American Capital Agency Corp (NASDAQ:AGNC), (NYSE:BABA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . PBR: 13.20 (-0.80), QLTI: 3.99 (unch), FE: 35.21 (+0.27), AGNC: 22.84 (+0.18), BABA: 90.90 (+2.64)
Endo Buyout Of Auxilium Joins Two Changing Firms
at Investor's Business Daily - Thu Oct 09, 6:00PM CDT
Endo International inked a deal to buy fellow specialty drugmaker Auxilium Pharmaceuticals Thursday after raising its initial bid by nearly 20% to $2.6 billion in cash and stock, or $33.25 a share. Auxilium's shares rose 9% to 32.44, while Endo's...
ENDP: 63.73 (+2.29), VRX: 130.38 (+5.60), QLTI: 3.99 (unch), AUXL: 31.12 (+0.53), VVUS: 3.47 (+0.02)
Nasdaq stocks posting largest volume increases
AP - Thu Oct 09, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
OFED: 18.50 (unch), QLTI: 3.99 (unch), QLT.TO: 4.49 (+0.01), TILE: 15.51 (+0.09), UNIS: 3.77 (+0.02), ARWR: 6.80 (+0.23), FSBW: 16.80 (+0.03), GTWN: 16.14 (-0.11), DYNT: 3.76 (-0.06), JAXB: 11.54 (+0.49), KFX: 6.04 (-0.01), OBCI: 4.41 (+0.21), ISSC: 2.72 (+0.17), AUXL: 31.12 (+0.53), ORBT: 2.42 (-0.08), LAKE: 14.94 (+0.01), GTIV: 19.39 (unch)
How Endo International's $2.6B Deal for Auxilium Benefits Shareholders
at The Street - Thu Oct 09, 12:53PM CDT
With this deal for Auxilium, Endo has just turned itself into a top-tier global specialty health care leader.
ENDP: 63.73 (+2.29), ABT: 42.39 (+0.93), QLTI: 3.99 (unch), ACT: 232.13 (+5.46), AUXL: 31.12 (+0.53)
Why Auxilium Pharmaceuticals Inc. Stock Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Thu Oct 09, 10:07AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Auxilium Pharmaceuticals soared over 10%...
QLTI: 3.99 (unch), AUXL: 31.12 (+0.53)
Stock Futures Down, Off Lows; Alcoa, United, Auxilium Rise
at Investor's Business Daily - Thu Oct 09, 8:10AM CDT
Stock futures trimmed losses agressively ahead of Thursday's open, after positive weekly unemployment numbers. Dow futures were down 54.2 points, but well above early lows. Nasdaq 100 futures traded 5.8 points below fair market value, halving their...
BLDP: 2.87 (unch), ENDP: 63.73 (+2.29), QLTI: 3.99 (unch), AA: 16.35 (+0.66), PLUG: 4.41 (-0.04), AUXL: 31.12 (+0.53), UAL: 49.51 (+2.22)
Endo Intl to buy Auxilium in deal worth $2.6B
By TOM MURPHY - AP - Thu Oct 09, 7:37AM CDT
Ireland's Endo International is planning to buy Auxilium Pharmaceuticals in a sweetened cash-and-stock deal valued at $2.6 billion a few weeks after Auxilium rejected a lower bid. The Auxilium board embraced the latest offer but its shareholders get to vote on it.
ENDP: 63.73 (+2.29), QLTI: 3.99 (unch), QLT.TO: 4.49 (+0.01), AUXL: 31.12 (+0.53)
QLT Announces Merger With Auxilium Pharmaceuticals, Inc. Terminates for Superior Proposal
GlobeNewswire - Thu Oct 09, 5:47AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
announces that it has been advised by Auxilium Pharmaceuticals, Inc. ("Auxilium" that Auxilium's board of directors has reviewed an offer from Endo International plc ("Endo" to acquire all of the issued and outstanding shares of Auxilium (the "Endo Proposal" and, after consulting with its financial advisors and outside legal counsel, has determined that the Endo Proposal is a superior proposal under the terms of the Agreement and Plan of Merger (the "Merger Agreement" among QLT, Auxilium, QLT Holding Corp., and QLT Acquisition Corp., dated June 25, 2014. Accordingly, Auxilium has delivered a notice of termination of the Merger Agreement and has, in accordance with the Merger Agreement, agreed to concurrently pay to QLT a termination fee in the amount of US$28.4 million. QLTI: 3.99 (unch), QLT.TO: 4.49 (+0.01), AUXL: 31.12 (+0.53)
QLT Enters Oversold Territory
MarketNewsVideo.com - Thu Sep 25, 12:39PM CDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
QLTI: 3.99 (unch)
The Zacks Analyst Blog Highlights: Auxilium Pharmaceuticals, QLT, Endo International, Gilead and Regeneron
PR Newswire - Thu Sep 25, 9:04AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Auxilium Pharmaceuticals (Nasdaq:AUXL-Free Report), QLT Inc. (Nasdaq:QLTI-Free Report), Endo International plc (Nasdaq:ENDP-Free Report), Gilead (Nasdaq:GILD-Free Report) and Regeneron (Nasdaq:REGN-Free Report).
QLTI: 3.99 (unch), AUXL: 31.12 (+0.53)
Biotech Stock Roundup: Auxilium an Acquisition Target, Amgen Submits another BLA - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 24, 10:05AM CDT
Auxilium Pharmaceuticals' (AUXL) shares soared almost 45% on a $2.2 billion acquisition proposal from Endo.
ENDP: 63.73 (+2.29), QLTI: 3.99 (unch), VRTX: 108.16 (+3.39), SHPG: 185.80 (+1.21), AUXL: 31.12 (+0.53), ALXN: 174.48 (+6.28), AMGN: 144.09 (+6.58), ABBV: 56.29 (+1.88), REGN: 381.01 (+14.88)
Auxilium Pharmaceuticals Favors QLT Deal Over Endo Bid - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 1:54PM CDT
Auxilium Pharmaceuticals (AUXL) has rejected Endo's (ENDP) offer.
ENDP: 63.73 (+2.29), QLTI: 3.99 (unch), AUXL: 31.12 (+0.53), AMGN: 144.09 (+6.58)
Auxilium Says Endo Takeover Offer Undervalues Company
at Investor's Business Daily - Mon Sep 22, 3:38PM CDT
Auxilium Pharmaceuticals' (AUXL) board said Monday that a $2.2 billion takeover offer from Endo International "significantly undervalues" the company. But the specialty-drug maker stopped short of an outright rejection of the unsolicited takeover bid...
ENDP: 63.73 (+2.29), QLTI: 3.99 (unch), AUXL: 31.12 (+0.53)
QLT Provides Further Update on Merger With Auxilium Pharmaceuticals, Inc.
GlobeNewswire - Mon Sep 22, 7:07AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
announces that it has been advised by Auxilium Pharmaceuticals, Inc. ("Auxilium" that Auxilium's board of directors (the "Auxilium Board" has reviewed the unsolicited offer from Endo International plc ("Endo" to acquire all of the issued and outstanding shares of Auxilium (the "Endo Proposal" and, after consulting with its independent financial and legal advisors, has unanimously determined that the Endo Proposal is not a superior proposal under the terms of the Agreement and Plan of Merger (the "Merger Agreement" among QLT, Auxilium, QLT Holding Corp., and QLT Acquisition Corp., dated June 25, 2014. Auxilium has further advised that the Auxilium Board has unanimously reaffirmed its recommendation that Auxilium's stockholders vote in favor of the adoption of the Merger Agreement, and has not withdrawn, modified, withheld, changed or qualified its recommendation with respect to the proposed merger with QLT pursuant to the Merger Agreement. QLTI: 3.99 (unch), QLT.TO: 4.49 (+0.01), AUXL: 31.12 (+0.53)
Auxilium Pharma rejects Endo's takeover offer
AP - Mon Sep 22, 6:45AM CDT
CHESTERBROOK, Pa. (AP) — Auxilium Pharmaceuticals Inc.'s board has rejected an approximately $1.4 billion unsolicited takeover offer from Ireland's Endo International PLC.
ENDP: 63.73 (+2.29), QLTI: 3.99 (unch), QLT.TO: 4.49 (+0.01), AUXL: 31.12 (+0.53)
Auxilium Provides Transaction Update
PR Newswire - Mon Sep 22, 6:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that its Board of Directors (the "Board"
has reviewed the unsolicited, non-binding and conditional proposal from Endo International plc ("Endo" and, after consulting with its independent financial and legal advisors, has unanimously determined it is not a superior proposal under the terms of its existing merger agreement with QLT Inc. ("QLT" and has unanimously reaffirmed its recommendation that Auxilium's stockholders vote in favor of the adoption of such merger agreement. In addition, the Board has determined that Endo's proposal significantly undervalues Auxilium. However, under the terms of the merger agreement with QLT, Auxilium maintains the right to engage in discussions with Endo and other third parties, subject to certain conditions in the merger agreement. QLTI: 3.99 (unch), AUXL: 31.12 (+0.53)
Nasdaq stocks posting largest percentage decreases
AP - Thu Sep 18, 12:18PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ALCS: 0.30 (+0.01), QLTI: 3.99 (unch), QLT.TO: 4.49 (+0.01), RTRX: 9.49 (-0.11), BRID: 8.50 (+0.01), LPCN: 4.88 (+0.08), RPRX: 6.02 (-0.21), NYNY: 6.64 (-0.01), NVC.TO: 6.14 (+0.19), PEIX: 11.55 (unch), DGLY: 12.99 (-0.15), NVCN: 5.26 (+0.04)
